EASD: AstraZeneca’s Farxiga cuts blood sugar, weight and insulin use in Type 1 diabetes study | FiercePharma

AstraZeneca’s Farxiga is already battling it out with its SGLT2 rivals in Type 2 diabetes. But it may have a future in another field, too, if data from a new Type 1 study can expand its use.

Source: EASD: AstraZeneca’s Farxiga cuts blood sugar, weight and insulin use in Type 1 diabetes study | FiercePharma